Mifamurtide
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Mifamurtide |
| DrugBank ID | DB13615 |
| Brand Names (EU) | Mepact |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 93.06% |
Approved Indication (EMA)
Mepact is indicated in children, adolescents and young adults for the treatment of high-grade resectable non-metastatic osteosarcoma after macroscopically complete surgical resection. It is used in combination with postoperative multi-agent chemotherapy. Safety and efficacy have been assessed in studies of patients two to 30 years of age at initial diagnosis.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | filariasis | 93.06% | DL |
| 2 | primary hereditary glaucoma | 86.67% | DL |
| 3 | autoimmune oophoritis | 85.19% | DL |
| 4 | autosomal dominant familial hematuria-retinal arteriolar tortuosity-contractures syndrome | 84.06% | DL |
| 5 | type 1 diabetes mellitus | 83.77% | DL |
| 6 | brain small vessel disease 1 with or without ocular anomalies | 83.34% | DL |
| 7 | open-angle glaucoma | 82.86% | DL |
| 8 | cholecystolithiasis | 81.83% | DL |
| 9 | trigeminal autonomic cephalalgia | 77.84% | DL |
| 10 | diabetic nephropathy | 77.64% | DL |
| 11 | headache disorder | 76.60% | DL |
| 12 | thromboangiitis obliterans | 75.41% | DL |
| 13 | unclassified myelodysplastic syndrome | 73.37% | DL |
| 14 | refractory cytopenia of childhood | 71.80% | DL |
| 15 | partial deletion of the long arm of chromosome 5 | 71.78% | DL |
| 16 | myelodysplastic syndrome | 71.05% | DL |
| 17 | aregenerative anemia | 70.86% | DL |
| 18 | severe congenital hypochromic anemia with ringed sideroblasts | 70.39% | DL |
| 19 | tendinitis | 70.00% | DL |
| 20 | congenital hypotrichosis milia | 69.84% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.